ClinicalTrials.gg
RecruitingNCT05786274PASCALUpdated Jul 6, 2026

Predicting Cerebrovascular Adverse Events Post Cardiac Surgery

An interventional study of Cerebral autoregulation monitoring in Cardiac Disease, sponsored by IRCCS Policlinico S. Donato. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by IRCCS Policlinico S. Donato · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
104
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 102 studies in Heart Diseases with a site in Italy — 31 open to participants now, 40 under way, 4 of them phase 3. Heart Diseases · Italy.

Planned enrollment
51st of 66
104 · median 444
Started
2023
with 9 others
No phase
31 of 102
13 open now
Primary completion
2026-12
later than 14 of 39 live
Registered
71st of 102
by date
Lead sponsor
8 of 102
IRCCS Policlinico S. Donato

Among the 102 studies in Heart Diseases with a site in Italy, this one is the 51st largest by planned enrollment of the 66 interventional ones that give a count, is one of 10 that started in 2023, is one of 31 with no phase, reaches primary completion later than 14 of the 39 other live ones, and was the 71st registered.

Heart Diseases

2,135 studies on the registry are indexed under Heart Diseases; 250 are open to participants now.

Browse Heart Diseases studies →

Open to participants now

31 of the 102 studies in Heart Diseases with a site in Italy are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 182 Heart Diseases studies recruiting now, 128 (70%) set no upper age limit and 22 (12%) stop at 75 or younger; 33 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies in Heart Diseases with a site in Italy, or all of them as a file.
02

Study summary

The aims of this study are: i) to assess cerebral autoregulation and autonomic control within the different phases of cardiac surgery with cardiopulmonary bypass; ii) to compare cerebral autoregulation measures derived via cerebral blood flow velocity estimated by transcranial Doppler device with simpler measurements derived from near infrared spectroscopy; iii) to develop a predictive model of postoperative cerebrovascular outcome (overt or silent stroke) based on the extracted indices.

03

Conditions studied

  • Cardiac Disease

Keywords

  • cerebral autoregulation
  • cardiopulmonary bypass
  • stroke
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age older than 18 years
  • spontaneous sinus rhythm
  • no pregnancy
  • signed

Exclusion criteria

Exclusion Criteria:

  • age lower than 18 years
  • absence of sinus rhythm
  • autonomic disorders
  • concomitant carotid intervention
  • reintervention
  • to MRI
  • pregnancy
  • impossibility of
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
104 participants (estimated)

Study arms

  • Other
    Cardiac surgery with cardiopulmonary bypass patients

    Patients will be enrolled before cardiac surgery with cardiopulmonary bypass (CPB) and monitored until after the surgery. Patients enrolled will undergo diffusion weighted magnetic resonance imaging and will be administered with cognitive tests one day before surgery and within one week after surgery. Cerebral blood flow velocity as derived from transcranial Doppler recordings will be acquired from the middle cerebral artery synchronously with arterial pressure, invasively derived from the radial artery, and with the electrocardiogram as derived from patient's monitor. Signals will be acquired before anesthesia induction (BASAL), after anesthesia induction and intubation of the chest (ANESTH) and during CPB (CPB). Each acquisition will last at least 5 minutes and will be prolonged to the maximum possible length in keeping with clinical scheduling. Partial pressure of carbon dioxide and other clinical parameters will be acquired too during the intervention.

    Diagnostic Test: Cerebral autoregulation monitoring

Interventions

  • Diagnostic testCerebral autoregulation monitoring

    Perioperative characterization of cerebral autoregulation and autonomic function; characterization of adverse events after surgery

06

What researchers measure

Primary outcomes

  1. Autoregulation index (ARI)

    ARI is an index describing the state of cerebral autoregulation from mean cerebral blood velocity and mean arterial pressure. It ranges between 1 and 9. ARI\>4 means working autoregulation. ARI\<4 means impaired autoregulation. It will be computed for all participants in BASAL, ANESTH, CPB.

    Time frame: 36 months

  2. Cerebral Oxymetry index (CoX)

    CoX is an index describing the state of cerebral autoregulation derived from NIRS and mean arterial pressure. It ranges between 0 and 1. CoX = 1 means perfect coupling. Cox=0 means uncoupling. It will be computed for all participants in BASAL, ANESTH, CPBasurements derived from near infrared spectroscopy

    Time frame: 36 months

  3. number of patients developing cerebrovascular adverse events

    The number of patients developing cerebrovascular adverse events will be assessed by the presence of positive lesions as detected by DW-MRI.

    Time frame: 36 months

Secondary outcomes

  1. Baroreflex sensitivity

    Baroreflex sensitivity will be measured in ms/mmHg. A higher value means a better baroreflex regulation. It will be computed in all participants during BASAL, ANESTH, CPB.

    Time frame: 36 months

07

Study locations

1 of 1 sites recruiting
  • IRCCS Policlinico San Donato
    San Donato Milanese, Milan 20097, Italy
    Recruiting
    • Vlasta Bari, PhD · Contactvlasta.bari@grupposandonato.it · +390252774381
    • Beatrice Cairo, PhD · Sub investigator
    • Moreno Zanardo, PhD · Sub investigator
    • Giacomo Bortolussi, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Dec 2026, 44 months after the start.

Of 264 non-industry interventional studies with no phase under Heart Diseases, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's planned 44 months is above that.

Counting every sponsor, half of 337 studies reached it within 25 months; a quarter within 11 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2023
First posted
Mar 27, 2023
StartActual
Apr 1, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05786274
Collaborators
University of Milan
Responsible party
Vlasta Bari (Principal Investigator, IRCCS Policlinico S. Donato) — Principal investigator
First posted
Mar 27, 2023
Start date
Apr 1, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 6, 2026

Study contacts

Vlasta Bari, Ph.D.
Contact
vlasta.bari@grupposandonato.it
0252774381
Giacomo Bortolussi, M.D.
Contact
giacomo.bortolussi@grupposandonato.it
0252774754

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion